(NASDAQ: LTRN) Lantern Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.25%.
Lantern Pharma's earnings in 2025 is -$19,248,695.On average, 1 Wall Street analyst forecast LTRN's earnings for 2025 to be -$19,546,945, with the lowest LTRN earnings forecast at -$19,546,945, and the highest LTRN earnings forecast at -$19,546,945. On average, 1 Wall Street analyst forecast LTRN's earnings for 2026 to be -$12,311,335, with the lowest LTRN earnings forecast at -$12,311,335, and the highest LTRN earnings forecast at -$12,311,335.
In 2027, LTRN is forecast to generate -$17,495,056 in earnings, with the lowest earnings forecast at -$17,495,056 and the highest earnings forecast at -$17,495,056.